Drug Manufacturing in Space

NASA, Varda Space Industries and Bristol Myers Squibb are among the named organizations working in this field. NASA provides research and flight opportunities aboard the ISS; Varda is developing orbital manufacturing and return infrastructure. Bristol Myers Squibb has collaborated with Redwire on ISS research into small-molecule crystallization. Their work spans research access, production infrastructure and drug-focused investigations.

Varda Space Industries and BioOrbit have concrete commercial signals in 2026. Varda announced a pharmaceutical formulation partnership with United Therapeutics in May, while BioOrbit announced a £9.8 million seed round in April. Cospace is another relevant startup; it has patented equipment for microgravity protein crystallization and monitoring crystal growth. These activities indicate distinct routes: orbital manufacturing, pharmaceutical partnerships and specialized research equipment.

The University of Nottingham and German Aerospace Center are among the research organizations studying pharmaceutical behavior in spaceflight. With the University of Adelaide, they examined melatonin-loaded nanoemulsions flown on the MAPHEUS-15 sounding rocket. Butler University also engages in microgravity protein crystallization and in-space pharmaceutical manufacturing, including work related to Redwire's Pharmaceutical In-space Laboratory.

Topic-tagged records report $14,735,353 in grants across 24 awards since 2020. A separate company announcement reported BioOrbit's £9.8 million seed round in April 2026. These figures come from different funding sources and currencies, so they should not be combined as a single total. The available records also include funding outside the space-manufacturing focus, making individual deal context important.

Bausch Strobel Se Co. Kg is the leading listed holder, with 4 patents. Clearside Biomedical and Arranta Bio Holdings LLC each have 3. B. Braun Group, Qilu Pharmaceutical Co., Glaukos, The Regents of the University of California and Georgia Techn Research Corporation each have 2. These are the leading holders in the available patent-holder data.

No: the available data records 72 patents in the defined window and reports patent growth of -28.6%. Publication activity is moving in the other direction: 166 publications were recorded last year, up 27.7%. This contrast suggests that research interest is increasing while patenting has recently slowed; it does not establish whether individual processes are commercially ready.

Drug manufacturing in space is still developing, with research and early commercial partnerships rather than routine production. Varda Space Industries announced a formulation partnership with United Therapeutics in May 2026, and the UK set out a regulatory pathway for biologics made in space in March 2026. Spaceflight stability studies also continue. Product quality, repeatable production and viable return logistics remain important tests.

The main approaches are protein crystal growth, small-molecule crystallization, mammalian-cell biomanufacturing, microbial fermentation and biologic formulation. Crystallization uses microgravity to explore crystal growth and drug forms; cell culture and fermentation use living production systems; formulation focuses on product stability and delivery. Each addresses different products and process steps, and each must demonstrate reliable control under spaceflight conditions.

The United States has the most country-tagged records, with 6,185, followed by the United Kingdom with 2,298 and Germany with 2,143. These country figures can overlap, so they should not be read as exclusive shares of global activity. Named activity includes NASA research opportunities, UK regulatory and company initiatives, and German Aerospace Center participation in spaceflight formulation research.